Immunotherapy of mouse leukemia with monoclonal antibodies directed against type-C virus structural proteins.
The monoclonal antibody A6, isolated during a study on the natural immunoresponse of BALB/c mice against leukemia cells (4), reacts with the envelope glycoproteins gp70 of the MuLV and with the cell surface of the SL2 AKR leukemia. In the present paper, we describe the in vivo immunotherapeutic effect exerted by the A6 monoclonal antibody on the growth of the transplanted leukemia SL2. The greater therapeutic effect observed when the A6 was used with exogenous complement cooperation suggests that the immunotherapeutic activity is mediated by C'-dependent cytotoxicity.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000914:Antibodies, Viral / Q000276:immunology; D000918:Antibody Specificity; D000956:Antigens, Viral / Q000276:immunology; D001202:Ascitic Fluid / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006023:Glycoproteins / Q000276:immunology* / Q000302:isolation & purification; D007167:Immunotherapy; D009052:Leukemia Virus, Murine / Q000276:immunology*; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; C033589:glycoprotein gp70, murine serum; D003165:Complement System Proteins